Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 18;22(12):6532.
doi: 10.3390/ijms22126532.

Ovarian Cancer Immunotherapy and Personalized Medicine

Susan Morand  1 , Monika Devanaboyina  1 , Hannah Staats  1 , Laura Stanbery  2 , John Nemunaitis  2
Affiliations
Review

Ovarian Cancer Immunotherapy and Personalized Medicine

Susan Morand et al. Int J Mol Sci. .

Abstract

Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.

Keywords: biomarker; immunotherapy; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Howlader N., Cronin K.A., Kurian A.W., Andridge R. Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol. Biomark. Prev. 2018;27:619–626. doi: 10.1158/1055-9965.EPI-17-0627. - DOI - PubMed
    1. Foley O.W., Rauh-Hain J.A., Del Carmen M.G. Recurrent epithelial ovarian cancer: An update on treatment. Oncology. 2013;27:288. - PubMed
    1. Cortez A.J., Tudrej P., Kujawa K.A., Lisowska K.M. Advances in ovarian cancer therapy. Cancer Chemother. Pharmacol. 2018;81:17–38. doi: 10.1007/s00280-017-3501-8. - DOI - PMC - PubMed
    1. Baldwin L.A., Huang B., Miller R.W., Tucker T., Goodrich S.T., Podzielinski I., DeSimone C.P., Ueland F.R., van Nagell J.R., Seamon L.G. Ten-year relative survival for epithelial ovarian cancer. Obstet. Gynecol. 2012;120:612–618. doi: 10.1097/AOG.0b013e318264f794. - DOI - PubMed